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Abstract 
 Background: Asian patients with acute coronary syndrome (ACS) are frequently 
prescribed moderate-intensity statin in real practice, even during the early stage of 
ACS. Under assessment herein was the effect of moderate-intensity statin therapy 
on the resolution of plaque inflammation during the first month after ACS, a 
period with highest recurrent ischemic events, using dual time point 18F-
fluorodeoxyglucose positron emission tomography/computed tomography (FDG 
PET/CT). 
Methods: This prospective study included statin-naïve patients with ACS and 
non-calcified carotid plaques ( 3 mm on ultrasound images). Baseline FDG 
PET/CT images of the carotid arteries of the patients were obtained. Then, all 
patients received atorvastatin (20 mg/day); follow-up FDG PET/CT images of the 
carotid arteries were then obtained after 1 month of therapy. The primary endpoint 
measurement was the change in the target-to-background ratio (TBR) of the 
carotid artery between the initial and follow-up FDG PET/CT scans. 
Results: Thirteen ACS patients completed the initial and follow-up FDG PET/CT 
scans. Moderate-intensity statin therapy failed to reduce plaque inflammation at 1 
month after ACS (TBR 1.60 ± 0.20 at baseline vs. 1.50 ± 0.40 after therapy; p = 
0.422) but significantly reduced serum low-density lipoprotein cholesterol (LDL-
C) levels (mean LDL-C 101.2 ± 21.1 mg/dL at baseline vs. 70.7 ± 12.4 mg/dL 
after therapy; p < 0.001). Changes in the TBR and serum LDL-C levels were not 
correlated (r = –0.27, p = 0.243). 
Conclusions: Dual time point FDG PET/CT imaging demonstrates that moderate-
intensity statin therapy was insufficient in  suppressed plaque inflammation 
within the first month after ACS in Asian patients, even though achieving target 
LDL levels.  
Key words: statin, 18F-FDG PET/CT, low-density lipoprotein cholesterol, 
acute coronary syndromes 
  
 
Introduction 
High-intensity statin therapy has significantly improved the clinical outcomes 
of patients with acute coronary syndrome (ACS). Because the greatest risk for 
recurrent cardiovascular (CV) events occurs during the first month after ACS [1, 
2], the early initiation of high-intensity statin therapy in ACS patients at the time 
of intense vascular inflammation improves their CV prognosis by systematically 
stabilizing highly inflamed plaques. Indeed, a previous study demonstrated the 
benefits of early statin therapy in reducing ischemic events within 30 days 
subsequent to ACS [3]. 
Statins are prescribed at lower starting doses to patients at risk of developing 
side effects: Asian, female, those with smaller body frame, age exceeding 65 years, 
kidney or liver disease, or excessive alcohol consumption. Asian patients 
especially, receive lower doses of statin in most clinical settings compared with 
their Western counterparts [4]. In clinical practice, only 14.2% of Korean ACS 
patients received high-intensity statin therapy even after percutaneous coronary 
intervention (PCI) [5]. Moreover, in the 2013 ACC/AHA guidelines, Asian 
ancestry is considered as a characteristic that might modify a decision to use high-
intensity statin therapy [6]. However, no evidence exists that moderate-intensity 
statin therapy is sufficient to resolve plaque inflammation in earlier stages of ACS 
in Asians. 
To address this issue, dual time point 18F-fluorodeoxyglucose positron 
emission tomography/computed tomography (FDG PET/CT) imaging of carotid 
arteries was used. FDG PET/CT provides a noninvasive measure of carotid plaque 
inflammation in patients [7] and successfully monitors alterations in plaque 
inflammation following therapy with simvastatin [8, 9] and antioxidant probucol 
 [10]. Under investigation in this study was the effect of moderate-intensity statin 
therapy on plaque inflammation in early-stage non-ST-segment elevation (NSTE)-
ACS patients by performing a longitudinal spatial assessment of statin-modulated 
alterations of carotid FDG uptake. An assessment was also made as to whether 
changes in plasma low-density lipoprotein cholesterol (LDL-C) levels, a clinical 
marker of statin efficacy, correlated with changes in carotid FDG uptake.  
 
Methods 
Design and subjects 
This study was a prospective observational study involving statin treatment 
and imaging assessment of atherosclerotic plaque inflammation using dual time 
point FDG PET/CT scans of carotid arteries. The study protocol was approved by 
the institutional review board of Seoul St. Mary’s Hospital, Seoul, Korea 
(KC09MISV0195). All subjects provided written informed consent. Patients were 
eligible for this study if they presented with NSTE-ACS, underwent PCI and had 
non-calcified atherosclerotic plaques ≥ 3 mm in carotid arteries, as identified 
using cervical ultrasound (US) examination (Fig. 1). Patients with any of the 
following conditions were excluded: statin or thiazolinedione therapy within the 
prior 4 weeks; elevated liver enzyme levels ( 2.5 times the normal upper limit); 
congestive heart failure of New York Heart Association (NYHA) classification 
class 2 to 4; age < 18 years; and pregnancy. All patients first underwent initial 
FDG PET/CT scans of their carotid arteries within 7 days after index PCI, 
followed by statin treatment. One month later, follow-up FDG PET/CT scans of 
the carotid arteries were performed.  
 
Statin therapy 
All study subjects received 20 mg atorvastatin immediately after baseline 
 FDG PET/CT scanning. All medications, including antidiabetic medications, 
antiplatelet agents and antihypertensive medications, taken by patients prior to 
baseline FDG PET/CT scanning were continued. 
 
18F-FDG PET/CT imaging 
After a minimum of 6 h of fasting, patients with blood sugar levels of less than 
130 mg/dL were intravenously administered approximately 10 mCi of 18F-FDG. 
Diabetic patients were instructed not to take oral anti-hyperglycemic agents or to 
inject insulins during fasting time. The patients were then encouraged to drink 
water and urinate often and had bed rest prior to image acquisition. 90 min after 
the FDG injection, PET/CT images of the neck region were obtained using a 
dedicated PET/CT scanner (High Definition Biograph Truepoint; Siemens, 
Germany). For carotid imaging, non-contrast-enhanced CT images were obtained 
from the skull base to the lower margin of the neck and were used for attenuation 
correction (40-section helical, 5 mm section slice). PET images were acquired at 
10 min per bed position, from approximately 2 to 4 beds. Contrast enhancement 
was not performed throughout PET/CT imaging. One month after atorvastatin 
therapy, follow-up PET/CT images of carotid arteries of 13 of the 20 patients were 
obtained using the same imaging protocol.  
 
18F-FDG PET/CT analysis 
The FDG-PET/CT images were visually evaluated for the presence of 
abnormal FDG uptake in the bilateral carotid arteries. FDG uptake in the arterial 
plaques was then quantified by measuring the standardized uptake value (SUV) 
corrected for body weight. The SUV was calculated usinga pixel activity value 
within the region of interest (ROI) placed on the entire vasculature obtained from 
consecutive, co-registered transaxial FDG-PET and non-contrast-enhanced CT 
 images. The SUVmax was recorded as the highest pixel activity value within the 
ROI for every slice of the vessel. The SUVmax was measured along carotid arteries 
at 5-mm intervals in an axial orientation. The mean SUVmax was calculated by 
averaging SUVmax values for all slices within arterial territories. The arterial 
target-to-background ratio (TBR) was calculated by dividing maximal arterial 
SUV by blood (jugular vein) FDG uptake to produce a blood-corrected arterial 
SUV (SUVcarotid/jugular). Additionally, metabolic lesion volumes (MLV) were 
computed for each patient’s carotid artery lesions by adding all pixels with SUVs 
greater than the designated cut-off values (SUV cutoff was set at 1.0, or SUVmax 
of neck muscle was used) in manually defined ROIs. Two nuclear medicine 
physicians who were blinded to patient clinical information performed FDG 
uptake measurements, which were then averaged. When the difference in 
measurements between the two readers was greater than 20%, a third nuclear 
medicine physician helped to reach a consensus. The change in TBR (TBR) was 
defined as the difference in TBR between baseline and follow-up PET/CT images 
of the neck.  
The primary endpoint value was the absolute change in TBR within an index 
vessel after 1 month of atorvastatin therapy. The index vessel was defined as the 
carotid artery in which plaque buildup was detected using cervical ultrasound 
before treatment. In cases where both carotid arteries had detectable plaque 
buildup, the artery with the higher FDG uptake was chosen as the index vessel.  
 
18F-FDG PET/CT reproducibility test  
FDG PET/CT reproducibility tests were performed at the participating 
institution using phantoms asa requisite condition for enrollment in unrelated 
international drug trials. The various PET/CT system parameters were also 
assessed for quality control on a daily and bimonthly basis as part of a routine 
 clinical practice.  
 
Measurement of blood metabolic, lipid, and inflammatory parameters 
Blood was collected before and 1 month after atorvastatin therapy for the 
measurement of serum metabolic, lipid, and inflammatory parameters. Fasting 
serum glucose, total cholesterol, triglyceride, direct LDL-C and direct high-
density lipoprotein cholesterol (HDL-C) levels were measured using a Hitachi 
7600 automatic chemistry analyzer (Hitachi Co., Tokyo, Japan) with reagents 
obtained from Sekisui Medical (Tokyo, Japan). High-sensitivity C-reactive 
protein (hsCRP) levels were measured using an immunoturbidimetric assay with 
reagents obtained from Wako Pure Chemical Industries (Osaka, Japan) and a 
Hitachi 7600 automatic chemistry analyzer. Serum insulin levels were measured 
according to the radioimmunoassay method using an immunoradiometric assay kit 
obtained from Dinabot Co. (Tokyo, Japan). Plasma matrix metalloproteinase-9 
(MMP-9), monocyte chemoattractant protein-1 (MCP-1) and plasminogen 
activator inhibitor-1 (PAI-1) levels were measured using enzyme-linked 
immunosorbent assay (ELISA) kits (R&D systems, MN, USA). The homeostatic 
model assessment (HOMA) index was calculated based on serum glucose and 
insulin levels.  
 
Statistical analysis 
Assuming that 20% of patients would not be available for dual time point 
PET/CT, it was estimated that 18 patients would provide 80% power to detect an 
absolute decrease of 0.15 or greater in TBR, with a standard deviation of 0.2 and α 
= 0.05 using 20 mg atorvastatin, based on the findings of a previous study [8]. 
Statistical analyses were performed using SPSS (v18.0; San Diego, CA). Data 
are expressed as the mean ± standard error of the mean (SEM). Paired Student t-
 test was used to assess differences in FDG uptake and blood parameters before 
and after therapy. Unpaired Student t-tests were used to test differences in the 
FDG uptake and blood parameters according to statin response. Spearman’s 
correlation coefficients (r-values) were calculated for correlations. A p-value of 
less than 0.05 was considered statistically significant. 
 
Results 
Characteristics of the study population 
Twenty statin-naïve patients who underwent PCI and were found to have non-
calcified plaques in their carotid arteries consented to undergo dual time point 
FDG PET/CT studies of their carotid arteries, and 13 patients completed both pre- 
and post-statin FDG PET/CT scans and laboratory exams (Fig. 1). 11 male and 2 
female patients were included, with a mean age of 67.3 years (52–78 years). 9 
patients presented with unstable angina, and 4 patients presented with NSTE 
myocardial infarction (NSTEMI). All patients received aspirin and clopidogrel. 7 
patients had diabetes mellitus and all of them were using oral hypoglycemic 
agents. The clinical profile and PCI data are summarized in Table1.  
 
Treatment effects of moderate-intensity atorvastatin on plasma lipid, metabolic 
and inflammatory parameters 
Statin therapy significantly reduced serum total cholesterol (p < 0.001) and 
triglyceride (p = 0.033) levels. Serum LDL-C levels markedly decreased from 
101.2 ± 21.1 mg/dL to 70.7 ± 12.4 mg/dL (p < 0.001) following 1 month of statin 
therapy (Table 2). However, no change in serum HDL-C levels was observed. 
After statin therapy, 5 patients had follow-up serum LDL-C levels greater than 70 
mg/dL but less than 90 mg/dL. In contrast to these improved lipid profiles, plasma 
inflammatory markers such as hsCRP, MMP-9 and MCP-1 were not significantly 
 reduced despite statin therapy. Only PAI-1 responded to one-month statin therapy 
(p = 0.003).  
 
Dual time point FDG PET/CT of carotid arteries 
As assessed by 90-min post-FDG PET/CT images, no significant difference 
was noted in FDG uptake parameters before and after statin therapy (Table 2). 
Baseline and follow-up TBR values (1.60 ± 0.2 vs. 1.50 ± 0.40, respectively) were 
not significantly different (p = 0.422). Additionally, statin therapy did not alter any 
other FDG uptake parameter: (1) SUVmax (baseline 2.2 ± 0.5 vs. post-statin 2.0 ± 
0.3, p = 0.174); (2) the MLV of carotid lesions with a fixed SUV cutoff of 1.0 
(MLV1.0; baseline 705.4 ± 724.2 mm3 vs. post-statin 733.1 ± 1,213.1 mm3, p = 
0.926); (3) MLV with each patient’s sternocleidomastoid (SCM) muscle SUVmax 
as the cutoff (MLVSCM; baseline 1,683.8 ± 1,612.5 mm3 vs. 1,149.2 ± 872.6 mm3, 
p = 0.349). When individually analyzed, nine patients had decreased TBR values 
at follow-up (“statin-responder by PET” group; Fig. 2A), and 4 patients showed 
similar or paradoxically increased TBR despite adequate statin therapy (“statin-
non-responder by PET” group; Fig. 2B, C). The mean follow-up plasma LDL-C 
levels were 69.8 ± 13.7 mg/dL in the “statin-responder by PET” group and 72.9 ± 
9.9 mg/dL in the “statin-nonresponder by PET” group, and no significant 
difference was found between the two groups (p = 0.691).  
Comparison of changes in the blood inflammatory markers and FDG uptake 
parameters between patients with post-statin LDL levels of less than and greater 
 than 70 mg/dL 
No differences in blood inflammatory parameters, including hsCRP, MMP-9, 
MCP-1 and PAI-1, or in FDG PET/CT parameters, including the mean SUVmax, 
TBR, MLV1.0 and MLVSCM were observed between the two groups (Table 3).  
 
Comparison of changes in the blood inflammatory marker between statin 
responder by PET and non-responder  
The inflammatory markers and FDG uptake markers were compared between 
PET-CT responder and non-responder. There were significant differences in 
MMP-9 change (ΔMMP-9) (baseline-follow-up) (responder –1.99 ± 3.02 vs. 3.04 
± 2.31, p = 0.042), however no significant differences were noted in other 
inflammatory markers (Table 4). 
 
Correlation between plasma LDL-C levels and carotid FDG uptake 
No correlation was observed between baseline serum LDL-C levels and the 
TBR (r = –0.57, p = 0.54) and between LDL-C and TBR (r = –0.35, p = 0.264). 
Additionally, no significant correlations were found between LDL-C and 
changes in three other FDG uptake parameters were SUVmax, MLV1.0 and 
MLVSCM (r = –0.15, p = 0.623; r = 0.268, p = 0.377; and r = 0.600, p = 0.067, 
respectively). In the analysis between FDG uptake parameters and inflammatory 
markers, no correlation was observed between ΔTBR and changes in 
inflammatory markers ΔCRP, ΔMMP-9, ΔPAI-1 and ΔMCP-1 (r = –0.086, p= 
0.872; r = –0.667, p = 0.071; r = –0.591, p = 0.056; r = –0.471, p = 0.265)  
 
Discussion 
In this prospective dual time point study of carotid FDG uptake, moderate-
intensity statin therapy occasionally failed to suppress plaque inflammation in 
 ACS patients. Although moderate-intensity statin therapy successfully achieved 
target plasma LDL-C levels of approximately 70 mg/dL in all patients with ACS, 
about 31% (4 out of 13) patients failed to lower the levels of plasma and imaging 
biomarkers of plaque inflammation during the early stage following ACS, 
whereas 69% (9 out of 13) succeeded.  
The early initiation of high-intensity statin therapy significantly improved 
early and late clinical outcomes in ACS patients compared with standard-dose 
statin therapy [11, 12]. Observational studies have also supported the early use of 
high-intensity statin therapy in ACS patients [13]. However, many practitioners 
believe that Asians require lower statin doses [4], and the recommended doses of 
most statins approved in Japan are indeed much lower than those in the US [14]. A 
JAPAN-ACS study further demonstrated that 20 mg/day of atorvastatin led to the 
significant regression of coronary atherosclerosis after 8–12 months of therapy 
[15]. However, no studies have validated the hypothesis that moderate-intensity 
statin therapy is sufficient to reduce plaque inflammation within 30 days after 
ACS in Asian patients.  
 FDG PET/CT was employed in this study, which can precisely map, quantify, 
and track alterations in statin-induced plaque inflammation, to image carotid 
arteries [8]. Additionally, all patients selected who presented with NSTE-ACS and 
were treated with drug-eluting stent (DES) implantation and dual antiplatelet 
therapy; thus, the anti-inflammatory effect of statins on atherosclerotic plaques 
could be observed exclusively. Although the systemic inflammatory state in ACS 
can affect carotid plaque inflammation, the choice to include ACS patients in this 
study was made. Although statins exert both systemic and local effects during this 
critical period after ACS, and the degree of statin efficacy differs when acting 
systemically versus locally, statin therapy should nevertheless suppress the 
inflammatory burden in carotid plaques. With this unique study design, it was  
 observed that moderate-intensity statin therapy during the first month after ACS 
often succeeds but sometimes fails to resolve plaque inflammation in Asian 
patients.  
Notably, poor correlations were observed both between changes in carotid 
FDG uptake parameters and those in LDL-C levels and between changes in 
carotid FDG uptake parameters and other plasma inflammatory markers following 
statin therapy during the acute period of ACS. In contrast, previous studies have 
shown associations between reduced carotid FDG uptake and decreased LDL-C 
levels [9] and between decreased MMP-1 and hsCRP levels [16, 17]. The 
following factors might have contributed to this discrepancy between FDG uptake 
and blood metabolic and inflammatory markers: (1) Inadequacy of serum LDL-C 
levels as a barometer of plaque inflammation, especially in the highly vulnerable 
period followed by plaque rupture; (2) Shortcomings of the clinical FDG PET/CT 
system currently used to quantify the inflammatory state in atherosclerotic lesions; 
and/or (3) Insufficiency of the duration of medication to clarify a mutual 
correlation; (4) Change in FDG uptake contributable to factors other than that of 
statin [18]. Atherosclerotic plaques are often dynamic in vivo and the FDG uptake 
is often transient throughout longitudinal clinical course with or without specific 
treatments [19, 20]. 
Using FDG uptake to measure the number and metabolic activity of 
macrophages in a given plaque and measuring serum LDL concentrations may be 
incongruent because these measures represent two closely related but distinct 
aspects of complex activities in a vulnerable plaque. Indeed, LDL-C might not 
mark all of the benefits of statin therapy, and there is insufficient evidence to state 
that achieving target LDL-C levels (< 70 mg/dL) will decrease CV events in the 
critical period after ACS [21]. In terms of FDG uptake, although the change in 
vascular inflammation independent of stain was not excluded (i.e. changes in the 
 course of ACS), it is reasonable to expect statin does contribute to vascular 
inflammatory status, but may depend on the dosage.  
 
Limitations of the study 
This study has several limitations. First, the duration of moderate-intensity 
statin therapy only lasted for one month; this period may be insufficient to draw a 
firm conclusion regarding whether moderate-intensity statin therapy can reduce 
plaque inflammation in Asian ACS patients. Most similar studies demonstrating 
the anti-inflammatory action of statins on plaques used treatments lasting 3 
months [8, 22]. However, the objective of this study was to investigate whether 
moderate-intensity statin therapy was sufficient to resolve plaque inflammation 
within the first month after ACS, which represents the period of highest risk for 
recurrent CV events. A previous study showed that the effect of statins on 
reducing FDG uptake can be observed within as early as 4 weeks and that this 
reduction was in turn correlated with a further reduction after 12 weeks [22]. 
Additionally, a small, randomized study in Asian ACS patients showed that 
fluvastatin exerted a significant dose-dependent anti-inflammatory effect in as 
early as 1 week [23]. Consequently, the authors hypothesized that the anti-
inflammatory effect of moderate-intensity statin therapy might be observed and 
measured using PET/CT within as early as 4 weeks after therapy if the statin is to 
be effective. If statin therapy is as effective as currently believed, the intensity of 
statin therapy rather than the 4-week time frame likely dictates the outcome. This 
needs to be studied separately in a similar patient population. 
Second, the present study lacks a control group. The results of a single group 
“before-after” study such as the present one should be interpreted with caution. 
The result of the present study should not be considered conclusive on thequestion 
as to whether moderate-intensity statin is justified in treating Asian NSTE-ACS 
 patients. Although not conclusive, the results presented suggest that because 
moderate-intensity statin therapy inconsistently “cool down” inflammatory status 
in atherosclerotic plaques in this study population, high-dose statin therapy might 
be more beneficial for patients with certain ACSs, even in patients at risk of 
developing statin side effects. 
Third, the conclusion of this study is based on a small number of patients who 
underwent initial and follow-up FDG PET/CT scans. Regrettably, there were 
difficulties in recruiting patients who met our strict inclusion criteria consenting to 
undergo two FDG PET/CT exams. Thus, there was an inability to draw definitive 
conclusions. Although the sample was small, it showed that 30% of ACS patients 
exhibited significant carotid plaque inflammation despite good statin compliance 
and the achievement of target LDL goals and that moderate-intensity statin 
therapy is insufficient during an early stage after ACS.  
Fourth, in the analysis of FDG PET/CT imaging, plaques 3 mm or greater on 
carotid artery US were selected and this criterion may have been an insufficient 
predictor of true plaque inflammation. The measured TBR as well as LDL levels 
were relatively low and the present patient group may not represent patients with 
a heavy inflammatory burden of plaques. 
Additionally, the non-enhance CT used in the present FDG PET/CT imaging 
may have limited the resolution of atherosclerotic plaques. 
 
Conclusion 
In summary, by using dual time point FDG PET/CT images of carotid arteries 
in ACS patients, this study demonstrates that early moderate-intensity statin 
therapy does not guarantee resolution of atherosclerotic plaque inflammation after 
1 month of statin therapy and the present data indicate it may fail in 30% of 
patients. Furthermore, plasma LDL-C levels do not reflect the status of local 
 plaque inflammation. 
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Table 1 Baseline characteristics of patients in the study (n = 13). 
  
Age [years] (range) 67.3 (52–78) 
Male  11 (84.6%) 
Diagnosis at presentation:  
Unstable angina 9 (69.2%) 
       NSTEMI 4 (30.8%) 
Hypertension  9 (69.2%) 
Diabetes mellitus  7 (53.8%) 
Current smoker  3 (23.1%) 
BMI [kg/m2] 24.7 ± 2.5  
  
Atorvastatin dose: 20 mg 13 (100%) 
Other medications:  
Aspirin 13 (100%) 
Clopidogrel 13 (100%) 
ARB/ACEI 12 (92.3%) 
β-blocker  10 (76.9%) 
PCI data:  
Three vessel disease 3 (23.0%) 
 Two vessel disease 3 (23.0%) 
One vessel disease 7 (53.8%) 
Mean stent diameter [mm] 3.08 ± 0.29  
Total stent length [mm] 39.4 ± 20.4  
Total number of stent 1.69 ± 0.85 
 Number of B2 or C 0.77 ± 0.83 
Peak creatinine kinase-MB [ng/mL]  159.2 ± 165.3  
Peak troponin I [ng/mL] 132.2 ± 143.9  
ARB/ACEI — angiotensin receptor blocker/angiotensin-converting enzyme inhibitor; 
BMI — body mass index; NSTEMI — non-ST-segment elevation myocardial infarction; 
PCI — percutaneous coronary intervention 
 
 
 
Table 2 Baseline and post-statin therapy values of serum lipid, metabolic and 
inflammatory markers as well as fluorodeoxyglucose (FDG) uptake parameters. 
 Baseline Post-statin P  
Total cholesterol [mg/dL] 163.9 ± 18.5 129.0 ± 18.6 < 0.001 
Triglycerides [mg/dL] 131 ± 81.9 99.5 ± 51.8 0.033 
LDL cholesterol [mg/dL] 101.2 ± 21.1 70.7 ± 12.4 < 0.001 
HDL cholesterol [mg/dL] 36.5 ± 8.1 38.4 ± 9.3 0.373 
Glucose [mg/dL] 126.5 ± 32.9 107.0 ± 14.2 0.029 
hsCRP [mg/dL] 0.60 ± 0.82 0.21 ± 0.24 0.073 
MMP-9 [ng/mL] 3.6 ± 2.8 3.7 ± 3.0 0.935 
PAI-1 [ng/mL] 40.4 ± 23.6 21.6 ± 11.0 0.003 
MCP-1 [pg/mL] 32.7 ± 21.1 33.0 ± 9.0 0.965 
Mean SUVmax 2.2 ± 0.5 2.0 ± 0.3 0.174 
TBR 1.6 ± 0.2 1.5 ± 0.4 0.422 
MLV1.0 [mm3] 705.4 ± 724.2 733.1 ± 1213.1 0.926 
 MLVSCM [mm3] 1683.8 ± 1612.5 1149.2 ± 872.6 0.349 
HDL — high-density lipoprotein; hsCRP — high-sensitivity C-reactive protein; LDL — 
low-density lipoprotein; MCP-1 — monocyte chemoattractant protein-1; MLV1.0 — 
metabolic lesion volume computed using an SUV cutoff of 1.0; MLVSCM — metabolic 
lesion volume computed using an SUV cutoff of sternocleidomastoid muscle; MMP-9 — 
matrix metalloproteinase-9; PAI-1 — plasminogen activator inhibitor-1; SUVmax — 
maximum standardized uptake value; TBR — ratio of the maximum standardized uptake 
value of the carotid plaque over the maximum standardized uptake value of the jugular 
vein 
 
 
 
Table 3 Comparison of the changes in plasma inflammatory markers and 
fluorodeoxyglucose (FDG) uptake parameters between statin responders and statin non-
responders. 
Δparameters (baseline-follow 
up) 
Post-statin LDL-C ≤ 70 
mg/dL 
(n = 8) 
Post-statin LDL-C > 70 
mg/dL 
(n = 5) 
P  
ΔhsCRP [mg/dL] 0.34 ± 0.74 0.44 ± 0.58 0.814 
ΔMMP-9 [ng/mL] 0.18 ± 2.4 -0.40 ± 5.08 0.843 
ΔPAI-1 [ng/mL] 16.8 ± 21.3 21.7 ± 10.6 0.349 
ΔMCP-1 [pg/mL] –10.7 ± 7.8 7.9 ± 28.1 0.246 
Mean ΔSUVmax 0.1 ± 0.5 0.4 ± 0.5 0.356 
ΔTBR 0.1 ± 0.5 0.1 ± 0.3 0.926 
ΔMLV
1.0 [mm
3] –283.8 ± 1206.0 382.0 ± 649.2 0.825 
ΔMLV
SCM [mm
3] 113.8 ± 991.9 1208.0 ± 3013.4  0.354 
 — change; hsCRP — high-sensitivity C-reactive protein; MCP-1 — monocyte 
chemoattractant protein-1; MLV1.0 — metabolic lesion volume computed using  SUV 
cutoff of 1.0; MLVSCM — metabolic lesion volume computed using an SUV cutoff of 
sternocleidomastoid muscle; MMP-9 — matrix metalloproteinase-9; PAI-1 — 
plasminogen activator inhibitor-1; SUVmax — maximum standardized uptake value; TBR 
— ratio of maximum standardized uptake value of carotid plaque over maximum 
standardized uptake value of the jugular vein 
 
 
 
Table 4 Comparison of changes in plasma inflammatory markers and fluorodeoxyglucose 
(FDG) uptake parameters between positron emission tomography/computed tomography 
 (PET/CT) responders and non-responders. 
Δparameters (baseline-follow 
up) 
PET-CT responders 
(n = 9) 
PET-CT non-
responders 
(n = 4) 
P  
ΔTBR 0.59 ± 0.71 –0.64 ± 1.01 0.026 
ΔhsCRP [mg/dL] 0.44 ± 0.78 1.39 ± 1.46 0.332 
ΔMMP-9 [ng/mL] –1.99 ± 3.02 3.04 ± 2.31 0.042 
ΔPAI-1 [ng/mL] 18.5 ± 14.6 28.30 ± 20.15 0.501 
ΔMCP-1 [pg/mL] 4.63 ± 27.0 –10.29 ± 2.13 0.246 
 — change; hsCRP — high-sensitivity C-reactive protein; MCP-1 — monocyte 
chemoattractant protein-1; MMP-9 — matrix metalloproteinase-9; PAI-1 — plasminogen 
activator inhibitor-1; TBR — ratio of the maximum standardized uptake value of carotid 
plaque over the maximum standardized uptake value of the jugular vein 
 
 
 
Figure 1. Study design — flow chart of the patient enrollment process and study 
schema. 
 
Figure 2. 18F-fluorodeoxyglucose positron emission tomography/computed 
tomography (FDG PET/CT) images — representative dual time point FDG 
PET/CT images of carotid arteries according to the response to statin therapy. A. 
“Responder by FDG PET/CT”. Ill-defined FDG activity is noted in the bilateral 
carotid arteries of a 64-year-old male. Coronal and axial images were obtained 
before (left column) and after (right column) statin therapy. The PET image 
acquisition time was set at 10 min per bed to improve sensitivity. The red arrows 
point to the right carotid artery, and white arrows point to the left carotid artery. 
Focal FDG uptake in the periphery of the carotid arteries reveals a decreased 
intensity and extent after statin therapy, despite a post-statin low density 
lipoprotein cholesterol (LDL-C) level of 86 mg/dL (above the target LDL-C level). 
The ratio of the maximum standardized uptake value of carotid plaque over the 
maximum standardized uptake value of the jugular vein (TBR) changed from 1.59 
to 1.15, with baseline carotid maximum standardized uptake value (SUVmax) of 
2.24 and jugular vein SUVmax of 1.41, and follow-up carotid 1.70 and jugular 1.48. 
Black arrowheads point to focal calcifications in the right carotid artery wall, 
which does not correspond to the highest FDG uptake focus as previously 
reported [18] but rather functions as a landmark for analyzing dual time point 
images in this study. B. “Nonresponder by FDG PET/CT.” Multi-focal FDG 
 uptake areas are noted along the bilateral carotid arteries of a 56-year-old male. 
Coronal and axial images were obtained before (left column) and after (right 
column) statin therapy. The red arrows point to the right carotid artery, and the 
white arrows point to the left carotid artery. Post-statin images show a similar 
focal FDG uptake intensity and extent in the periphery of  carotid arteries 
compared with pre-statin images, despite a low post-therapy LDL-C level of 50.6 
mg/dL. TBR was essentially unchanged from 1.48 to 1.47, with baseline carotid 
SUVmax of 1.85 and jugular vein SUVmax of 1.25, and follow-up carotid 2.01 and 
jugular 1.37. C. “Nonresponder by PET/CT.” Ill-defined focal FDG uptake areas 
are present in the bilateral carotid arteries of a 78-year-old male. Coronal and 
axial images were obtained before (left column) and after (right column) statin 
therapy. Red arrows point to the right carotid artery, and white arrows to the left 
carotid artery. The FDG uptake in the periphery of carotid arteries shows a similar 
or increased intensity and extent after therapy, suggesting a lack of improvement 
in plaque inflammation despite a low post-therapy LDL-C level of 61 mg/dL. 
TBR was increased from 1.69 to 2.18, with baseline carotid SUVmax of 2.67 and 
jugular vein SUVmax of 1.58, and follow-up carotid 2.62 and jugular 1.20.  
 


